Clinical Trial: Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

U.S., Feb. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07428499) titled 'Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)' on Feb. 19.

Brief Summary: Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.

Study Start Date: April 01

Study Type: INTERVENTIONAL

Condition: Hereditary Angioedema (HAE) Hereditary Angioedema - T...